---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-098882"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T04:02:48.453414+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theriva VIRAGE Phase 2b: VCN-01+GA OS 10.8mo (HR0.57, p=0.055), PFS 7.0mo (HR0.55, p=0.011)

## Summary
- In FAS population, VCN-01 + GA improved median OS to 10.8 mo vs 8.6 mo (HR 0.57, p=0.055) and PFS to 7.0 vs 4.6 mo (HR 0.55, p=0.011).
- Patients receiving 2 VCN-01 doses starting GA cycle 4 had OS 14.8 vs 11.6 mo (HR 0.44, p=0.046) and PFS 11.2 vs 7.4 mo (HR 0.48, p=0.017).
- VCN-01 well tolerated; all 13 related serious adverse events resolved; common: flu-like symptoms (13.2%), transaminase increase (5.7%).
- Data to be presented at ESMO 2025 mini oral session on Oct 20; abstract published. Study met primary endpoints.

## SEC filing metadata
- accession: 0001104659-25-098882
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/0001104659-25-098882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925098882/tm2528558d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-098882
- JSON: https://secwatch.observer/filing/0001104659-25-098882.json
- Plain text: https://secwatch.observer/filing/0001104659-25-098882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.